| Field | Specification |
|---|---|
| Gene symbol | |
| Accession number | |
| Species | |
| Applications | |
| Reporter/Tag | |
| Selection marker | Blasticidin, N/A, Puromycin |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Background
Indoleamine 2,3-dioxygenase 1 (IDO1) is the rate-limiting enzyme in the kynurenine pathway, catalyzing the first step in tryptophan degradation. By depleting local tryptophan and generating immunosuppressive kynurenine metabolites, IDO1 establishes a microenvironment that suppresses effector T cell function, promotes regulatory T cell differentiation, and dampens antitumor immunity. IDO1 expression is induced by inflammatory signals such as interferon-gamma and is frequently upregulated in tumors and tumor-draining lymph nodes, where it contributes to immune evasion. Because of this role, IDO1 is a prominent target in cancer immunotherapy and immune tolerance research.
Product Description & Applications
The Human IDO1 shRNA Lentivirus delivers validated short hairpin RNA targeting IDO1 from a third-generation, self-inactivating lentiviral backbone. shRNA expression is driven by a U6 promoter, with a co-expressed fluorescent reporter (GFP or RFP) and antibiotic selection marker. VSV-G pseudotyping enables broad tropism across primary, suspension, and cryopreserved cells, and each shRNA is validated for at least 70% IDO1 knockdown by a fluorescence-based method.
High-titer particles are ultra-purified by PEG precipitation and sucrose gradient centrifugation. A shRNA set option provides a mix of two independent validated shRNAs plus a scrambled control. Applications include loss-of-function studies of tryptophan metabolism, tumor immune evasion, and immune tolerance.
About This Product
This validated shRNA lentivirus targeting IDO1 (NCBI Accession: NM_002164.6) delivers a 19–20 bp shRNA from a third-generation, self-inactivating lentiviral backbone. Expression is driven from a U6 Pol III promoter, with a constitutively expressed fluorescent reporter (GFP, GFP/Luc, RFP, RFP/Luc) and antibiotic selection marker (Blasticidin, Puromycin) co-expressed from the same vector. VSV-G pseudotyping enables broad cell tropism, including primary, suspension, and cryopreserved cell types.
Knockdown is validated using a proprietary bicistronic fluorescence assay in which the target mRNA is co-expressed fused to RFP alongside the shRNA-GFP construct. At least 70% reduction in RFP signal in GFP-positive cells confirms on-target activity — a more direct functional readout than transcript-level qPCR. Polyclonal stable lines can be generated by antibiotic selection within 10 days, preserving parental cell heterogeneity compared to single-clone CRISPR approaches.
Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.
Common customization requests
- Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
- Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
- Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
- Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
- Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).
Add-ons you can request
- Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
- Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
- Documentation: construct map/sequence confirmation package (as available) and batch documentation.
What to include in your request
- Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
- Insert sequence (FASTA) or reference ID, plus any required tags/mutations
- Promoter, reporter, and selection marker preferences
- Desired scale and preferred format (aliquots / concentration requests)
Email us at support@biohippo.com or use the Talk to a Scientist request form.
